Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.
Idera Pharmaceuticals Inc. (toll-like receptor (TLR) antagonists for autoimmune diseases and B-cell lymphomas) signed on Abbott Laboratories Inc. to develop a companion in vitro diagnostic for use with its Phase II IMO8400 B-cell lymphoma program. (May)
The Big Pharma will apply polymerase chain reaction (PCR) technology to detect, with high sensitivity and specificity, the MYD88 L265P oncogenic mutation in tumor samples. The mutation is a key...
